Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2007 3
2008 2
2009 1
2010 2
2011 3
2012 5
2013 4
2014 4
2015 4
2016 6
2017 3
2018 1
2019 1
2020 2
2021 1
2022 3
2023 10
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Results by year

Filters applied: . Clear all
Page 1
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
Loriot Y, Matsubara N, Park SH, Huddart RA, Burgess EF, Houede N, Banek S, Guadalupi V, Ku JH, Valderrama BP, Tran B, Triantos S, Kean Y, Akapame S, Deprince K, Mukhopadhyay S, Stone NL, Siefker-Radtke AO; THOR Cohort 1 Investigators. Loriot Y, et al. N Engl J Med. 2023 Nov 23;389(21):1961-1971. doi: 10.1056/NEJMoa2308849. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870920 Clinical Trial.
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.
Siefker-Radtke AO, Matsubara N, Park SH, Huddart RA, Burgess EF, Özgüroğlu M, Valderrama BP, Laguerre B, Basso U, Triantos S, Akapame S, Kean Y, Deprince K, Mukhopadhyay S, Loriot Y; THOR cohort 2 investigators. Siefker-Radtke AO, et al. Ann Oncol. 2024 Jan;35(1):107-117. doi: 10.1016/j.annonc.2023.10.003. Epub 2023 Oct 21. Ann Oncol. 2024. PMID: 37871702 Clinical Trial.
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Alekseev B, Rha SY, Merchan J, Goh JC, Lalani AA, De Giorgi U, Melichar B, Hong SH, Gurney H, Méndez-Vidal MJ, Kopyltsov E, Tjulandin S, Gordoa TA, Kozlov V, Alyasova A, Winquist E, Maroto P, Kim M, Peer A, Procopio G, Takagi T, Wong S, Bedke J, Schmidinger M, Rodriguez-Lopez K, Burgents J, He C, Okpara CE, McKenzie J, Choueiri TK; CLEAR Trial Investigators. Motzer RJ, et al. J Clin Oncol. 2024 Apr 10;42(11):1222-1228. doi: 10.1200/JCO.23.01569. Epub 2024 Jan 16. J Clin Oncol. 2024. PMID: 38227898 Free PMC article. Clinical Trial.
Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC.
Bogatsa E, Lazaridis G, Stivanaki C, Timotheadou E. Bogatsa E, et al. Among authors: timotheadou e. Cancers (Basel). 2024 Apr 23;16(9):1619. doi: 10.3390/cancers16091619. Cancers (Basel). 2024. PMID: 38730571 Free PMC article. Review.
Narrative Review of Drug-Associated Nail Toxicities in Oncologic Patients.
Emvalomati A, Oflidou V, Papageorgiou C, Kemanetzi C, Giannouli M, Kalloniati E, Efthymiadis K, Koukoutzeli C, Timotheadou E, Trigoni A, Patsatsi A, Lazaridou E, Apalla Z, Trakatelli M. Emvalomati A, et al. Among authors: timotheadou e. Dermatol Pract Concept. 2023 Jan 1;13(1):e2023064. doi: 10.5826/dpc.1301a64. Dermatol Pract Concept. 2023. PMID: 36892360 Free PMC article. Review.
CA-125 KELIM as an Alternative Predictive Tool to Identify Which Patients Can Benefit from PARPi in High-Grade Serous Advanced Ovarian Cancer: A Retrospective Pilot Diagnostic Accuracy Study.
Zouzoulas D, Tsolakidis D, Tzitzis P, Chatzistamatiou K, Theodoulidis V, Sofianou I, Grimbizis G, Timotheadou E. Zouzoulas D, et al. Among authors: timotheadou e. Int J Mol Sci. 2024 May 11;25(10):5230. doi: 10.3390/ijms25105230. Int J Mol Sci. 2024. PMID: 38791269 Free PMC article.
Management of Cancer-associated Thrombosis (CAT): Symptomatic or Incidental.
Papakotoulas P, Tsoukalas N, Christopoulou A, Ardavanis A, Koumakis G, Papandreou C, Papatsimpas G, Papakostas P, Samelis G, Andreadis C, Aravantinos G, Ziras N, Kalofonos C, Samantas E, Souggleri M, Makrantonakis P, Pentheroudakis G, Athanasiadis A, Stergiou H, Tripodaki S, Bokas A, Grivas A, Timotheadou E, Bournakis E, Varthalitis I, Boukovinas I. Papakotoulas P, et al. Among authors: timotheadou e. Anticancer Res. 2020 Jan;40(1):305-313. doi: 10.21873/anticanres.13954. Anticancer Res. 2020. PMID: 31892581
The Utility of NGS Analysis in Homologous Recombination Deficiency Tracking.
Tsantikidi A, Papadopoulou E, Metaxa-Mariatou V, Kapetsis G, Tsaousis G, Meintani A, Florou-Chatzigiannidou C, Gazouli M, Papadimitriou C, Timotheadou E, Kotsakis A, Boutis A, Boukovinas I, Kampletsas E, Kontovinis L, Fountzilas E, Andreadis C, Karanikiotis C, Filippou D, Theodoropoulos G, Özdoğan M, Nasioulas G. Tsantikidi A, et al. Among authors: timotheadou e. Diagnostics (Basel). 2023 Sep 15;13(18):2962. doi: 10.3390/diagnostics13182962. Diagnostics (Basel). 2023. PMID: 37761329 Free PMC article.
60 results